Valneva SE
Specialty vaccine company developing and commercializing vaccines for infectious diseases.
VLA | PA
Overview
Corporate Details
- ISIN(s):
- AT0000A10B99 (+3 more)
- LEI:
- 969500DIVIP5VKNW4948
- Country:
- France
- Address:
- 6 RUE ALAIN BOMBARD, 44800 SAINT-HERBLAIN
- Website:
- https://valneva.com/
- Sector:
- Manufacturing
Description
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2013-04-02 08:02 |
VIVALIS ANNONCE LA SOUMISSION DE LA 1ERE DEMANDE D'AUTORISATION DE MISE SUR LE …
|
French | 85.4 KB | ||
| 2013-03-26 17:40 |
VIVALIS PUBLIE SES RESULTATS 2012
|
French | 79.3 KB | ||
| 2013-03-26 17:40 |
CONSOLIDATED 2012 FINANCIAL RESULTS
|
English | 113.9 KB | ||
| 2013-03-26 08:00 |
VIVALIS : NOUVELLE ETAPE DANS LE DEVELOPPEMENT DE LA LIGNEE CELLULAIRES EB66®
|
French | 477.0 KB | ||
| 2013-03-26 08:00 |
VIVALIS: EXPANDED DEVELOPMENT OF EB66® AS PART OF THE GLAXOSMITHKLINE INFLUENZA…
|
English | 416.9 KB | ||
| 2013-03-18 08:30 |
VIVALIS : ACTIONS ET DROITS DE VOTE FÉVRIER 2013
|
English | 6.8 KB | ||
| 2013-03-07 19:01 |
Les actionnaires de Vivalis SA et d'Intercell AG approuvent la fusion entre ég…
|
French | 269.5 KB | ||
| 2013-03-07 19:01 |
Vivalis SA and Intercell AG shareholders approved the proposed merger of equal…
|
English | 269.2 KB | ||
| 2013-02-28 08:03 |
L'Assemblée générale extraordinaire d'Intercell AG a approuvé la proposition d…
|
French | 35.7 KB | ||
| 2013-02-28 08:03 |
Vivalis announces that the Intercell AG Extraordinary General Meeting has appro…
|
English | 42.8 KB | ||
| 2013-02-14 17:40 |
VIVALIS ANNOUNCES FOURTH QUARTER 2012 RESULTS
|
English | 101.1 KB | ||
| 2013-02-14 17:40 |
VIVALIS PUBLIE SES RESULTATS POUR LE 4EME TRIMESTRE 2012
|
French | 71.1 KB | ||
| 2013-02-12 17:40 |
VIVALIS ANNONCE LA SIGNATURE D'UNE NOUVELLE LICENCE DE RECHERCHE POUR L'UTILISA…
|
French | 72.2 KB | ||
| 2013-02-12 17:40 |
VIVALIS ANNOUNCES A NEW EB66® CELL LINE RESEARCH LICENSE WITH A NORTH AMERICAN …
|
English | 74.1 KB | ||
| 2013-02-11 17:40 |
VIVALIS SPECIAL AND COMBINED SHAREHOLDERS MEETINGS TO BE HELD MARCH 7, 2013
|
English | 75.6 KB |
Automate Your Workflow. Get a real-time feed of all Valneva SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valneva SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valneva SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-03-18 | N/A | Other | Buy | 44,222 | N/A |
| 2024-01-03 | N/A | Other | Other | 34,802 | N/A |
| 2023-06-20 | N/A | Other | Sell | 192,547 | 1,406,228.50 EUR |
| 2023-06-19 | N/A | Other | Sell | 30,661 | 209,629.26 EUR |
| 2023-06-16 | N/A | Other | Sell | 85,589 | 582,493.06 EUR |
| 2023-06-15 | N/A | Other | Sell | 28,179 | 189,503.78 EUR |
| 2023-06-14 | N/A | Other | Sell | 228,951 | 1,519,914.11 EUR |
| 2023-06-13 | N/A | Other | Sell | 29,401 | 187,922.37 EUR |
| 2023-06-12 | N/A | Other | Sell | 117,854 | 733,782.57 EUR |
| 2023-05-10 | N/A | Other | Buy | 87,523 | N/A |
Peer Companies
